Upstream / Downstream
Explore pathways related to this product.
CST Antibody Performance Guarantee
Find answers on our FAQs page.
PTM information and tools available.
Di-Methyl-Histone H3 (Lys4) Antibody #9726
This product is discontinued
Di-Methyl-Histone H3 (Lys4) Antibody specificity was determined by peptide ELISA. The graphs depict the binding of the antibody to pre-coated di-methyl-histone H3 (Lys4) peptide in the presence of increasing concentrations of various competitor peptides. As shown, only the di-methyl-histone H3 (Lys4) peptide competed away binding of the antibody. The antibody does show slight cross-reactivity with mono-methyl-histone H3 (Lys4).Learn more about how we get our images
Gallery: Di-Methyl-Histone H3 (Lys4) Antibody #9726
Di-Methyl-Histone H3 (Lys4) Antibody detects endogenous levels of histone H3 when di-methylated on Lys4. The antibody shows very slight cross-reactivity with mono-methylated Lys4, but does not cross-react with non-methylated or tri-methylated Lys4. In addition, the antibody does not cross-react with mono-methylated, di-methylated or tri-methylated histone H3 at Lys9, Lys27, Lys36 or histone H4 at Lys20.Species predicted to react based on 100% sequence homology: Xenopus, Zebrafish
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to the amino terminus of histone H3 in which Lys4 is di-methylated. Antibodies are purified by peptide affinity chromatography.
The nucleosome, made up of four core histone proteins (H2A, H2B, H3, and H4), is the primary building block of chromatin. Originally thought to function as a static scaffold for DNA packaging, histones have now been shown to be dynamic proteins, undergoing multiple types of post-translational modifications, including acetylation, phosphorylation, methylation, and ubiquitination (1). Histone methylation is a major determinant for the formation of active and inactive regions of the genome and is crucial for the proper programming of the genome during development (2,3). Arginine methylation of histones H3 (Arg2, 17, 26) and H4 (Arg3) promotes transcriptional activation and is mediated by a family of protein arginine methyltransferases (PRMTs), including the co-activators PRMT1 and CARM1 (PRMT4) (4). In contrast, a more diverse set of histone lysine methyltransferases has been identified, all but one of which contain a conserved catalytic SET domain originally identified in the Drosophila Su(var)3-9, Enhancer of zeste, and Trithorax proteins. Lysine methylation occurs primarily on histones H3 (Lys4, 9, 27, 36, 79) and H4 (Lys20) and has been implicated in both transcriptional activation and silencing (4). Methylation of these lysine residues coordinates the recruitment of chromatin modifying enzymes containing methyl-lysine binding modules such as chromodomains (HP1, PRC1), PHD fingers (BPTF, ING2), tudor domains (53BP1), and WD-40 domains (WDR5) (5-8). The discovery of histone demethylases such as PADI4, LSD1, JMJD1, JMJD2, and JHDM1 has shown that methylation is a reversible epigenetic marker (9).
Product Specific References
Protein Specific References
For Research Use Only. Not For Use In Diagnostic Procedures. Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.